Edition:
India

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

227.16USD
23 Oct 2020
Change (% chg)

$-0.82 (-0.36%)
Prev Close
$227.98
Open
$228.72
Day's High
$230.07
Day's Low
$226.35
Volume
782,526
Avg. Vol
1,171,764
52-wk High
$264.97
52-wk Low
$177.05

Select another date:

Thu, Sep 17 2020

UPDATE 2-Lilly, Amgen partner to manufacture potential COVID-19 drugs

Sept 17 Eli Lilly and Co on Thursday partnered with Amgen Inc to increase the supply of its experimental COVID-19 antibody treatments, a day after one of Lilly's drugs was shown to reduce the need for hospitalization.

Lilly, Amgen partner to manufacture potential COVID-19 drugs

Eli Lilly and Co has partnered with Amgen Inc to increase the supply of its experimental COVID-19 antibody treatments, a day after one of the drugs was shown to reduce the need for hospitalization.

Lilly partners with Amgen for manufacturing potential COVID-19 drugs

Sept 17 Eli Lilly and Co on Thursday entered into an agreement with Amgen Inc to increase the supply capacity of the drugmaker's experimental COVID-19 antibody treatments.

UPDATE 2-Amgen second-quarter revenue rises 6%, shares fall 2%

July 28 Amgen Inc said on Tuesday second-quarter revenue rose 6% as higher sales of newer drugs, including recently added psoriasis treatment Otezla, offset declining sales of older medicines which were due in some cases to people staying home to avoid exposure to the new coronavirus.

Amgen second-quarter revenue rises 6%, adjusted profit tops Street view

July 28 Amgen Inc on Tuesday reported second-quarter revenue rose 6% as higher sales of newer drugs, including recently-added psoriasis treatment Otezla, offset declining sales of older medicines.

Amgen patents on top-selling arthritis drug Enbrel upheld, shares rise

A U.S. appeals court on Wednesday upheld two patents for Amgen Inc's multibillion-dollar rheumatoid arthritis drug Enbrel in a defeat for Novartis AG, which has been trying to sell its own version.

UPDATE 2-Amgen patents on top-selling arthritis drug Enbrel upheld, shares rise

July 1 A U.S. appeals court on Wednesday upheld two patents for Amgen Inc's multibillion-dollar rheumatoid arthritis drug Enbrel in a defeat for Novartis AG , which has been trying to sell its own version.

Amgen defeats Novartis appeal over arthritis drug Enbrel's patents

A federal appeals court on Wednesday upheld two patents for Amgen Inc's multibillion-dollar rheumatoid arthritis drug Enbrel, rejecting Novartis AG's effort to void the patents.

Amgen defeats Novartis appeal over arthritis drug Enbrel's patents

July 1 A federal appeals court on Wednesday upheld two patents for Amgen Inc's multibillion-dollar rheumatoid arthritis drug Enbrel, rejecting Novartis AG's effort to void the patents.

BRIEF-Amgen Is Supporting Advancement Of AMG 634 For Global Health Diseases In Developing Countries

* AMGEN IS SUPPORTING ADVANCEMENT OF AMG 634 FOR GLOBAL HEALTH DISEASES IN DEVELOPING COUNTRIES Source text for Eikon: Further company coverage:

Select another date: